Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for THALIDOMIDE
- Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients
- Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia
- Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
- Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
- Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC
- Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
- Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
- Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
- Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
- A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
- Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
- Lenalidomide in the Treatment of Mucosal Behçet's Syndrome
- Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
- Efficacy and Safety of Topical Nicotinamide in Treatment of Discoid Lupus Erythematosus
- Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
- Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC
- Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD
- Clinical Experience of Thalidomide in Thalassemic Patients
- Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
- MInimal Residual Disease Adapted Strategy
- Lenalidomide and Dexamethasone for Rosai-Dorfman Disease
- Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
- A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
- Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding
- Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis
- Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
- Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma
- TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL
- Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
- Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
- Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
- Isotretinoin in Treatment of COVID-19
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
- Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
- Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
- The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19
- The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia
- Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
- R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
- Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis
- Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
- MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
- Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
- Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
- Pomalidomide for the Treatment of Bleeding in HHT
- Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
- STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
- Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
- The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol
- Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum
- CURATE.AI Optimized Modulation for Multiple Myeloma
- Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia
- VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
- A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
- The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
- Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis
- The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
- Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
- Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
- Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
- Effect of Memantine on Radiotherapy-related Cognitive Impairment
- EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
- Study of VTD in Waldenstrom's Macroglobulinemia
- Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients
- Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
- Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)
- Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
- A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis
- Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
- The Therapeutic Effect of Thalidomide in RI
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
- The Effective and Safety of Thalidomide in TI
- Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
- Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
- Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
- TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
- Thalidomide Maintenance Treatment in DLBCL
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients
- The Effective and Safety of Thalidomide in NTDT
- Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis
- Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide
- Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
- A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
- Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
- Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma
- Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
- EDOCH Alternating With DHAP for New Diagnosed Younger MCL
- The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
- Prevention of Irinotecan Induced Diarrhea by Probiotics
- A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis
- Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis
- Conmana Combined With Thalidomide to Treat NSCLC
- Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding
- Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical
- Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
- the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation
- Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer
- Pembrolizumab (MK-3475) in MM Patients With Residual Disease
- Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure
- STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
- Clarithromycin in Multiple Myeloma Induction Therapy
- Modified Bortezomib-based Combination Therapy for Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
- Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
- Thalidomide in Treating Crohn's Disease
- The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy
- Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance
- Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
- Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
- Optimising Renal Outcome in Myeloma Renal Failure
- Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
- Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
- Gefitinib Combined With Thalidomide to Treat NSCLC
- Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma
- Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
- Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment
- An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement
- Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
- Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
- Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
- Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
- Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
- Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
- Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis
- Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
- Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
- Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Azithromycin in Idiopathic Pulmonary Fibrosis
- Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
- Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
- UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
- Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
- Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
- Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
- Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
- Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
- Thalidomide in the Treatment of Chronic Plaque Psoriasis.
- Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
- Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
- 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
- Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
- Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
- Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
- Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
- Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
- Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
- ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors
- Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
- Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
- Pomalidomide for Chronic Graft-versus-Host Disease
- Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
- Treatment of Peripheral T-cell Lymphoma
- Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
- Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
- THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure
- Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation
- Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
- A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
- Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
- Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer
- Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
- Velcade (Bortezomib) Consolidation After Transplant
- Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years
- Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
- Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
- Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
- Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
- Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma
- Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus
- Two Cycles of PAD Combination by AHCT in MM
- Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT
- THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
- Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
- A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
- Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma
- Prevention of Treatment Induced Neuropathy in Multiple Myeloma
- A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma
- Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant
- Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
- Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
- Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
- Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
- Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
- Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
- Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors
- Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
- Lenalidomide and Paclitaxel in Advanced Solid Tumors
- Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients
- VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
- Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome
- Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
- Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
- Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
- Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma
- Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
- Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
- Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
- Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
- Thalidomide Low Threshold in Epilepsy
- Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
- S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma
- Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis
- Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders
- Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
- Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
- The Treatment of Lenalidomide in Patients With POEMS Syndrome
- Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
- Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
- Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
- RMPT for Relapsed/Refractory Multiple Myeloma
- Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
- Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)
- A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
- A Study of High-Risk Oral Cavity Cancer
- Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
- Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
- Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)
- Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone
- Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer
- Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
- UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance
- Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma
- Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
- Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes
- Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
- Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
- Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE
- CC-4047 (Pomalidomide) for Graft vs. Host Disease
- Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
- A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
- Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis
- Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
- S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
- Thalidomide in Pediatric Inflammatory Bowel Diseases.
- Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
- Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)
- Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
- A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
- Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
- Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
- Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
- Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
- Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma
- Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
- Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
- A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
- Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
- Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
- A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)
- 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
- Effects of Exercise in Combination With Epoetin Alfa
- UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
- Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
- The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome
- Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
- UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma
- Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
- Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
- A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
- The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
- Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
- High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
- Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
- UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma
- Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
- Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
- Biochemotherapy With Temozolomide for Metastatic Melanoma
- Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma
- Sunscreen RV 2457C in Photoinduced CLE
- Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis
- Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.
- A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
- Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
- GEM05 for Patients With Multiple Myeloma Under 65 Years
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
- Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200
- Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
- R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
- Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
- GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
- VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
- ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
- Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
- Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
- Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
- Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
- Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
- Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
- Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
- Montelukast in ENL Reaction
- GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
- Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
- Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients
- Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
- A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- The Effects of Thalidomide on Symptom Clusters
- Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
- Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
- Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
- Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
- Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
- TCD Followed by autoSCT for Newly Diagnosed MM Patients
- A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
- VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates
- PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
- A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis
- Use of Thalidomide in Chronic Uveitis
- Trial of Adalimumab in Progressive Sarcoidosis
- Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
- Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
- Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
- SARCOTHAL. Thalidomide in Skin Sarcoidosis
- Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain
- Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
- REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
- Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
- Use of Thalidomide in Patients With Arachnoiditis
- Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
- Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
- Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
- Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
- Study of Velcade and Thalidomide in Patients With Myelodysplasia
- Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
- A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
- Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
- PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
- Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
- Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
- A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
- Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
- A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
- IFM 99-02 Thalidomide in Myeloma
- Thalidomide to Patients With Previously Untreated Multiple Myeloma
- Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
- Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease
- Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
- An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
- Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
- Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
- Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
- A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
- Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
- Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
- Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
- Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
- Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
- Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
- Phase II Study Using Thalidomide for the Treatment of ALS
- Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
- Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
- S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Evaluation of a TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect
- Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
- Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
- Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
- Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
- UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
- DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients
- S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
- Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
- A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
- Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
- PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
- Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
- Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm,
- Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
- A Phase II Study of CC-5013 in Myelofibrosis
- DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
- Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy
- D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma
- Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
- Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
- DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse
- Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
- UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
- Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
- Study of Combination PS-341 and Thalidomide in Multiple Myeloma
- Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
- Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
- UARK 2003-33, Total Therapy III
- An Open Protocol for the Compassionate Use of Thalidomide
- Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
- Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
- Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
- Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
- Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
- S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
- Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
- Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer
- Epirubicin and Thalidomide in Treating Patients With Liver Cancer
- A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
- Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
- Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People
- Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS
- Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
- Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
- Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
- Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
- Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
- Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
- Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
- Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
- Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
- Thalidomide for Multiple Myeloma
- Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
- Thalidomide-Dexamethasone for Multiple Myeloma
- CC-5013 in Treating Patients With Recurrent Glioma
- Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
- Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
- CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
- Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
- Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
- Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
- Thalidomide in Treating Patients With Thyroid Cancer
- Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
- Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
- Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
- Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
- Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
- Blood and Marrow Transplant Clinical Research Network
- Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
- Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
- Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
- Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma
- Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma
- Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer
- Thalidomide in Treating Patients With Myelodysplastic Syndrome
- Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Thalidomide in Treating Patients With Myelofibrosis
- Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
- Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
- Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
- Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
- Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
- Thalidomide and Dacarbazine for Metastatic Melanoma
- Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer
- Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
- Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed
- Thalidomide in Treating Patients With Gynecologic Sarcomas
- Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
- S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
- Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
- Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
- Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
- Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
- Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy
- Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections
- Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
- Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
- Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
- A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
- Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients
- Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
- A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
- Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV
- A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
- Pilot Study of Thalidomide to Treat Sjogren's Syndrome
- Thalidomide to Treat Oral Lesions in HIV-Infected Patients
- Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
- A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
- A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection
- Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection
Clinical trials list
click for details